LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

LLY

912.18

+0.56%↑

UNH

577.78

-0.27%↓

NVO

134.8

+1.94%↑

JNJ

165.28

-0.97%↓

ABBV

193.3

-0.33%↓

Inicio・Lista de Acciones・Alkermes PLC

Alkermes PLC

Cerrado

Sector Salud

27.77 0.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

27.55

Máximo

28.35

Métricas clave
By Trading Economics
Ingresos	55M 91M
Ventas	49M 399M
P/B Media del Sector	7.17 102.974
BPA	0.72
Margen de beneficio	22.891
EBITDA	68M 129M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+24.12 upside

Dividendos
By Dow Jones
Próximas Ganancias	23 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-132M 4.6B
Apertura anterior	27.55
Cierre anterior	27.77

Noticias sobre sentimiento de mercado

By Acuity

50%

122 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

26.75 / 27.85 Soporte y Resistencia

Alkermes PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 dic 2023, 11:06 UTC

Adquisiciones, fusiones, absorciones

Alkermes Athlone Facility Has About 400 Employees >ALKS

14 dic 2023, 11:06 UTC

Adquisiciones, fusiones, absorciones

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Comparación entre iguales

Cambio de precio

Alkermes PLC Esperado

Precio Objetivo

By TipRanks

24.12% repunte

Estimación a 12 meses

Media 34.43 USD 24.12%

Máximo 39 USD

Mínimo 28 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Alkermes PLC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

26.75 / 27.85Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

122 / 366 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.